Colitis Study: Ozanimod Tops Adalimumab, Equals Vedolizumab

In a statistical comparison, ozanimod matched vedolizumab and beat adalimumab for ulcerative colitis.

Related Keywords

New York ,United States ,Phoenix ,Arizona ,Jonathan Leighton ,Marla Dubinsky ,Pustekinumab Stelara ,Bristol Myers Squibb ,American College Of Gastroenterology ,Pfizer ,Drug Administration ,Pediatric Gastroenterology ,Icahn School ,Mount Sinai ,Medscape Medical ,True North ,American College ,Medscape Medical News ,Mayo Clinic ,Scientific Meeting ,Ulcerative Colitis ,Colitis ,Inflammatory Bowel Disease ,Nflammatory Bowel Disease Ibd ,Bd ,Anti Tnf ,Anti Tumor Necrosis Factor ,Biologic Therapy ,Clinical Research ,Clinical Trials ,Linical Studies ,Match ,Match Day ,Watch Application ,Atch Medical Students ,Medical Life ,Hysician Lifestyle ,Edical Lifestyle ,Esident Lifestyle ,Edical Student Lifestyle ,Urse Lifestyle ,Us Food And Drug Ad ,